Inventing new pharmaceuticals
Testing for biological activity of pharmaceuticals
Significance of preclinical data obtained with laboratory animals for humane application
First administration of new substance to humans
Laws and patent protection
Organisation dealing with pharmaceutical development
Managing the pharmaceutical problems within the European community
Pharmaceutical groups, new and old pharmaceuticals
Past, present, and future of pharmaceutical production
Pre-clinical safety assessment
Strategy and planning development of pharmaceutical form for new pharmaceuticals
Trials of pharmaceutical form suitable for pharmaceuticals under development
Biological accessibility and basic pharmacokinetic parameters
Control mechanisms in development of new pharmaceutical forms
Development of biotechnology
Novel pharmaceutical dosage forms and application methods
Role of state authorities in new pharmaceutical development process
Clinical trial within pharmaceutical company
Clinical trial plan
ICH - GCP
Principles of clinical trial design
Ethical aspects of clinical trial
Data management
Biostatistics in clinical trial
Quality control in clinical trial
Specific aspects of oncology pharmaceuticals, biotechnology products, OTC, psychiatric drugs and pediatric pharmaceuticals
Frauds and misconduct in clinical trial
Clinical trial from the viewpoint of investigators and customers
Summary report writing
Clinical trials, indemnity and the roles of sponsor and investigator
Introduction of pharmaceuticals into market
Principles and marketing practice
Product manager\\\\\\\\\\\\\\\'s activities
Marketing studies
Information on pharmaceuticals and their presentation
Advertising pharmaceutical products, code of practice / ethical rules for pharmaceutical marketing
Current legal regulations – National, European and differences in European countries
Legal environment for pharmaceutical development in the U.S.A. and Japan
Ethical committees\\\\\\\\\\\\\\\' activity
Informed consent, obtaining informed consent - European position
EMEA - Its structure and relationship with national authorities
Legal and ethical responsibilities of sponsor, investigation and study participants
Registration of new pharmaceuticals
Expert opinions on regulation of medicines and devices in Europe
Toxicology of pharmaceuticals
Safety pharmacology
Monitoring pharmaceutical safety in preclinical phase
Genotoxicity of pharmaceuticals
Reproductive toxicity
Pharmacogenomics
Clinical trial data analysis, analysis policy
Study power and sample size
Statistic evaluation of various clinical trial designs
Data management
Quality control for clinical trial statistic analysis
Communication between medical department and biostatisticians
Significance of clinical pharmacology in pharmaceutical development
Pharmacodynamics
Pharmacokinetics
Pharmacokinetics modeling
Therapeutic Drug Monitoring (TDM)
Interface between pharmacokinetic professionals and pharmacodynamic professionals
Pharmacotherapy
Special pharmacotherapeutical regimes for liver and kidney failures
History, principles and definitions
Classification of adverse reactions
Mechanisms of adverse effects
Monitoring pharmaceutical safety
European pharmacovigilance system
Data management and signal detection in respect of pharmaceutical safety
Determining causative connections and risk management
Pharmacoepidemiological study – basic principles, methodology
Legal rules and regulations for pharmacovigilance
Pharmaceutical safety and role of media
CIOMS, ICG, and current development of pharmacovigilance regulations
Financial management and corporate finance
Time, project, and human resources management
Principles of health economics
Health-related quality of life
Principles of pharmacoeconomics
Evidence Based Medicine
Costs of clinical trial management
The European Pharma School basic course is two year post-graduate level in pharmaceutical medicine. The course is organised into ten sessions, taking place once every two months, Thursday through to Saturday. The sessions cover the issues of the entire field.
Each session is a separate unit with an integrated summary related to the given topic.
Graduates of the basic study will be eligible for the advanced pharmaceutical medicine course. This advanced course deals with certain selected topics in much greater detail than the basic course, and thus, it complies with the requirements for higher level of education and training.
The lectures are equally divided between lecturers from the Czech Republic and foreign institutions. Foreign lectures will be simultaneously interpreted into Czech. Each session is coordinated by an expert in the field thus ensuring the quality of the programme.
Upon completion of the entire course the student will be awarded a diploma. Students may complete individual sessions or the entire course. After each session, a certificate of completion will be issued. Should a candidate wish to obtain a diploma for the entire basic two-year course, they will need to obtain certificates from all sessions within three years and pass a final written exam. After a successful completion, the candidate will receive a diploma certified by all the institutions involved. The diploma has European-wide validity.
After completion of the advanced course, the graduate may also apply to sit an exam with Cardiff University/Faculty of Pharmaceutical Medicine to obtain the British Diploma in Pharmaceutical Medicine. This Diploma is one of the highly recognised certificates and greatly contributes to the candidates future job prospects.
professionals working in pharmaceutical companies, contract research organisations, academia and regulatory authorities working in areas such as clinical development, registration, pharmacovigilance and marketing,
professionals from clinical departments of pharmaceutical companies that need international certification of their education,
professionals who need to be re-trained to return to an industry position following a break in their career,
graduates of the undergraduate course in pharmaceutical medicine at the 3rd School of Medicine of the Charles University.
Each section: CZK 45,000
Regular two-year tuition: CZK 350,000 (a ten-section program)
Start 2009
Three-day session: Thursday through Saturday once every two months (minimum required number of participants is ten).
Total of ten educational sessions during the two-year course.
EUROPEAN PHARMA
SCHOOL, s.r.o.
U Družstva Práce 734/43
Praha 4 - Podolí
Tel: +420 602 781 898
info@eps-eu.com
www.eps-eu.com